News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
357,461 Results
Type
Article (14352)
Company Profile (128)
Press Release (342981)
Section
Business (112575)
Career Advice (452)
Deals (18593)
Drug Delivery (25)
Drug Development (31133)
Employer Resources (49)
FDA (8787)
Job Trends (7663)
News (172647)
Policy (12351)
Tag
Academia (1315)
Alliances (34548)
Alzheimer's disease (440)
Approvals (8765)
Artificial intelligence (117)
Bankruptcy (129)
Best Places to Work (6423)
Biotechnology (97)
Breast cancer (46)
Cancer (437)
Career advice (403)
Cell therapy (129)
Clinical research (23721)
Collaboration (251)
Compensation (43)
COVID-19 (1109)
C-suite (50)
Data (416)
Diabetes (43)
Diagnostics (4704)
Earnings (37520)
Events (49933)
Executive appointments (134)
FDA (9012)
Funding (187)
Gene editing (46)
Gene therapy (86)
GLP-1 (184)
Government (1226)
Healthcare (9807)
Infectious disease (1148)
Inflammatory bowel disease (49)
Interviews (49)
IPO (7908)
Job creations (1436)
Job search strategy (361)
Layoffs (110)
Legal (2507)
Lung cancer (63)
Manufacturing (88)
Medical device (11296)
Medtech (11301)
Mergers & acquisitions (10752)
Metabolic disorders (110)
Neuroscience (523)
NextGen Class of 2024 (3530)
Non-profit (1511)
Northern California (571)
Obesity (56)
Opinion (65)
Patents (61)
People (32130)
Phase I (8740)
Phase II (10736)
Phase III (6941)
Pipeline (106)
Postmarket research (502)
Preclinical (3965)
Press Release (66)
Radiopharmaceuticals (147)
Rare diseases (76)
Real estate (3347)
Regulatory (9037)
Research institute (1265)
Resumes & cover letters (67)
Southern California (570)
Startups (2499)
United States (6012)
Vaccines (234)
Date
Today (113)
Last 7 days (441)
Last 30 days (1526)
Last 365 days (19218)
2024 (16264)
2023 (22096)
2022 (30813)
2021 (32514)
2020 (30541)
2019 (25801)
2018 (19461)
2017 (18877)
2016 (17763)
2015 (20562)
2014 (15177)
2013 (12743)
2012 (13782)
2011 (14066)
2010 (12826)
Location
Africa (316)
Arizona (93)
Asia (23582)
Australia (4106)
California (1352)
Canada (627)
China (106)
Colorado (78)
Connecticut (66)
Europe (48066)
Florida (219)
Georgia (70)
Illinois (154)
Indiana (84)
Kansas (75)
Maryland (281)
Massachusetts (988)
Michigan (129)
Minnesota (163)
New Hampshire (56)
New Jersey (444)
New York (406)
North Carolina (370)
Northern California (571)
Ohio (66)
Pennsylvania (298)
South America (506)
Southern California (570)
Texas (212)
Utah (50)
Washington State (208)
357,461 Results for "dynavax technologies".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Policy
FDA Rejects Dynavax’s Bid to Expand Use of Hepatitis B Vaccine
Dynavax Technologies announced Tuesday that the FDA issued a Complete Response Letter to the company’s sBLA to include a four-dose regimen of Heplisav-B vaccine for adult hemodialysis patients.
May 14, 2024
·
2 min read
·
Kate Goodwin
Biotech Bay
Dynavax to Present at Upcoming June 2024 Investor Conferences
Dynavax Technologies Corporation, a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, announced that the Company will present at the following upcoming investor conferences during the month of June.
May 28, 2024
·
1 min read
Drug Development
Dynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine Program
Dynavax Technologies Corporation (Nasdaq: DVAX) today announced that the first participant has been dosed in a Phase 1/2 clinical trial evaluating the safety, tolerability, and immunogenicity of Z-1018, the company’s investigational vaccine candidate being developed for the prevention of shingles (herpes zoster), a debilitating disease caused by the varicella-zoster virus.
June 27, 2024
·
4 min read
Press Releases
Dynavax Adopts Limited-Duration Stockholder Rights Plan
October 30, 2024
·
5 min read
Business
Dynavax Reports First Quarter 2024 Financial Results and Provides Business Updates
Dynavax Technologies Corporation, a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, reported financial results and provided a business update for the quarter ended March 31, 2024.
May 8, 2024
·
13 min read
Biotech Bay
Dynavax Provides Regulatory Update on sBLA for Four-Dose HEPLISAV-B® Regimen for Adults on Hemodialysis in the U.S.
Dynavax Technologies Corporation provided a regulatory update for the Company’s supplemental Biologics License Application to include a four-dose HEPLISAV-B® vaccine [Hepatitis B Vaccine, Adjuvanted] regimen for adults on hemodialysis.
May 14, 2024
·
5 min read
Business
Dynavax to Report First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report first quarter 2024 financial results on Wednesday, May 8, 2024, after the U.S. financial markets close.
April 24, 2024
·
1 min read
Business
Dynavax to Report Third Quarter 2024 Financial Results and Host Conference Call on November 7, 2024
October 24, 2024
·
1 min read
Biotech Bay
Dynavax to Present at TD Cowen’s 44th Annual Health Care Conference
Dynavax Technologies Corporation (Nasdaq: DVAX) today announced that the Company will present at TD Cowen’s 44th Annual Health Care Conference on Monday, March 4 at 10:30 a.m. ET.
February 27, 2024
·
1 min read
Business
Dynavax Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Financial Guidance
Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2023.
February 22, 2024
·
13 min read
1 of 35,747
Next